CDR acted for Aurobindo Pharma, a generics drugs manufacturer that is listed and headquartered in India, over allegations that its manufacturing processes contributed to the rise in antimicrobial resistance (AMR)


Aurobindo Pharma, which manufactures its drugs in Hyderabad, was the subject of a TV programme in the Netherlands that alleged that it contributed to pollution which was adding to the global crisis in AMR. Aurobindo decided to take the broadcaster to the press complaints body and hired CDR in the UK and the Netherlands to handle that and also provide media support globally around the issue.


A fully coordinated defensive communications plan by CDR’s London and Amsterdam offices, working with Aurobindo’s legal team, engaged with media globally. A central element of the plan was to educate media about manufacturing processes and the regulators accreditation of Aurobindo’s Indian plants.


Aurobindo’s link to AMR issues were kept to a minimum in media including in leading French, Dutch and North American publications and outlets.